Transient Pulses from Exploding Primordial Black Holes as a Signature of an Extra Dimension

An evaporating black hole in the presence of an extra spatial dimension would undergo an explosive phase of evaporation. We show that such an event, involving a primordial black hole, can produce a detectable, distinguishable electromagnetic pulse, signaling the existence of an extra dimension of size $L\sim10^{-18}-10^{-20}$ m. We derive a generic relationship between the Lorentz factor of a pulse-producing "fireball" and the TeV energy scale. For an ordinary toroidally compactified extra dimension, transient radio-pulse searches probe the electroweak energy scale ($\sim$0.1 TeV), enabling comparison with the Large Hadron Collider.Comment: 11 pages, 1 figure; references added; typos corrected; clarifying remarks added near the end of section

Single-field inflation, anomalous enhancement of superhorizon fluctuations, and non-Gaussianity in primordial black hole formation

We show a text-book potential for single-field inflation, namely, the Coleman-Weinberg model can induce double inflation and formation of primordial black holes (PBHs), because fluctuations that leave the horizon near the end of first inflation are anomalously enhanced at the onset of second inflation when the time-dependent mode turns to a growing mode rather than a decaying mode. The mass of PBHs produced in this mechanism lies in several discrete ranges depending on the model parameters. We also calculate the effects of non-Gaussian statistics due to higher-order interactions on the abundance of PBHs, which turns out to be small.Comment: 22pages, 8figure

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events